Volumetric Absorptive Microsampling (VAMS™), the technology behind Mitra® devices, retains the benefits of DBS cards while solving for their limitations.
Download these case studies from Exagen Diagnostics, GlaxoSmithKline, and others to see the following benefits vs DBS cards:
When Dried Blood Spot (DBS) cards debuted more than 50 years ago, they had significant advantages over traditional wet sampling, including simplicity, low cost, and ease of transportation.
But adoption has been hindered by regulatory concerns over the "Hematocrit (HCT) Effect," along with their automation limitations. In addition, incorrect spotting technique can lead to high sample rejection rates.
The FDA Class 1 Mitra® Microsampler is a novel specimen collection device that retains the advantages of Dried Blood Spot cards and solves for their limitations.